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Type 2 diabetes mellitus (T2DM) has a high prevalence and incidence around the world. The complex
pathophysiology mechanism is among the barriers for diabetes treatment. Type 2 diabetes patients have
dysfunction in incretin hormones (as glucagon-like peptide-1 or GLP-1, and glucose-dependent insulinotropic
polypeptide or GIP). By inhibiting the dipeptidyl peptidase-4 (DPP-4) enzyme, it is possible to slow the inactivation
of GLP-1 and GIP, promoting blood glucose level reduction in a glucose-dependent manner. Linagliptin is a highly
specific and potent inhibitor of DPP-4 that is currently indicated for the treatment of type 2 diabetes. Clinical
studies with linagliptin demonstrated efficacy in reducing glycated hemoglobin (HbA1c) levels in type 2 diabetes
patients, while maintaining a placebo-like safety and tolerability profile. Linagliptin has an interesting
pharmacokinetic profile in terms of its predominantly non-renal elimination and the main implication of this
characteristic is that no dose adjustment is necessary in patients with renal disease. Also, no dose adjustment is
required in patients with hepatic insufficiency, as well in elderly or obese patients. This article will review the
pharmacokinetic profile, efficacy data and safety aspects of linagliptin in type 2 diabetes patients.
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In recent decades, type 2 diabetes mellitus (T2DM) has
reached epidemic proportions in all regions of the
world, with increasing prevalence and incidence rates,
in parallel to the obesity epidemic and the dissemination
of occidental lifestyle [1]. It is estimated that in 2030,
T2DM will achieve about 300 million people worldwide
[2]. The micro- and macrovascular complications, asso-
ciated with chronic hyperglycemia, represent a major
public health problem. Cardiovascular diseases, blind-
ness, renal failure and limb amputations are responsible
for frequent hospitalizations and disabilities, resulting
in high economic cost for patients and payers [1]. Early
and intensive glycemic control is associated with reduc-
tion of these complications [3,4].
The pathophysiological defects involved in T2DM are
numerous and complex. Insulin resistance (IR) is an
event that precedes and predicts the hyperglycemia* Correspondence: erikapaniago@uol.com.br
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reproduction in any medium, provided the orcharacteristic of T2DM, persisting throughout the course
of the disease, and is therefore a therapeutic target in the
whole evolution process. The liver, muscles, and fat tissue
are directly involved in the IR mechanism [5]. The insulin
deficit is the mechanism that promotes the increase of
blood glucose levels, and at diagnosis of diabetes, the pa-
tient has already lost more than 80% of beta-cell function
[5]. However, new mechanisms are reformulating the
pathophysiological concept of T2DM, for example, the de-
fect in the incretin system (Glucagon-like peptide-1 or
GLP-1, and Gastric inhibitory polypeptide or GIP), pro-
moting hyperglycemia by less stimulation of insulin secre-
tion by pancreatic beta-cells, and less suppression of
glucagon release by pancreatic alpha-cells [1]. GLP-1 and
GIP are degraded by the dipeptidyl peptidase-4 (DPP-4)
enzyme immediately after their secretion by intestinal L-
cells [5]. DPP-4 inhibition is an important target for the
T2DM treatment, providing increased GLP-1 concentra-
tion, with consequent increase of insulin secretion by pan-
creatic βcells and reduction of glucagon secretion from
pancreatic α-cells, which in turn reduces hepatic glucose
output [6].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 In vitro selectivity of DPP-4 inhibitors (fold
selectivity for DPP-4 versus other enzymes) (Adapted
from Gupta et al.) [8]
Idpp4 FAPα DPP-8 DPP-9
Vildagliptin 285 270 32
Saxagliptin ? 390 77
Sitagliptin >5.500 >2.660 >5.550
Alogliptin >14.000 >14.000 >14.000
Linagliptin 89 40.000 >10.000
FAPα Fibroblast activation protein α, DPP-8 Dipeptidyl peptidase-8, DPP-9
Dipeptidyl peptidase-9.
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pharmacokinetic and pharmacodynamic characteristics
that differenciate it from other inhibitors on the market
[6]. In this article, aspects of the linagliptin pharmacology
will be reviewed, in addition to safety, tolerability and effi-
cacy data on monotherapy or combination therapy.
Pharmacological aspects
Chemical structure
The DPP-4 inhibitors can be divided, according to their
chemical structure, into those that mimic the DPP-4
molecule (vildagliptin and saxagliptin) and those that do
not (sitagliptin, alogliptin, and linagliptin). They inhibit
the DPP-4 enzyme by competition, acting extra-cellularly
[7]. The chemical structure of linagliptin (C25H28N802)
has a xanthine base, differing from other drugs of the
same class, and may reflect differences in pharmacokinetic
and pharmacodynamic properties (Figure 1) [8,9]. The
linagliptin also exhibits excellent selectivity for DPP-4
enzyme versus DPP-8 (40,000-fold) and DPP-9 (>10,000-
fold), and a low selectivity for fibroblast activation
protein-α (FAP-α) (Table 1) [6,7]. However, the DPP-8
and DPP-9 enzymes are intracellular and there is no evi-
dence that less selective inhibitors, such as saxagliptin
and vildagliptin, cross the cell membrane. Thus, despite
questioning the possibility of an increased risk of ad-
verse events with less selective inhibitors, the clinical
relevance and significance of this selectivity are not
established [6].
Pharmacokinetic and pharmacodynamic data
Linagliptin shows modest oral bioavailability, but is rap-
idly absorbed [9,10]. The maximum plasma concentra-
tion (Cmax) at steady state is reached on average 1.5
hours after administration of linagliptin 5 mg, once daily
[11]. Linagliptin half-life (t1/2) is 131 hours [12]. No rele-
vant food effects were observed on the absorption profile
of linagliptin [10].
A strong binding of the inhibitor to the DPP-4 enzyme
is important from the pharmacological point of view, toFigure 1 Chemical structure of the DPP-4 inhibitors [9,10].enable a 24-hour inhibition profile and the once-daily
dosing. Linagliptin is a competitive, selective and revers-
ible inhibitor, with ligand/receptor association (Ki) of
1 nmol/L, indicating strong binding, and a low dissoci-
ation rate of the enzyme [8,9]. The maximal efficacy for
in vitro DPP-4 inhibition is similar among all DPP-4
inhibitors, however linagliptin has greater potency (half
maximal [50%] inhibitory concentration or IC50 = ~1 nM
for linagliptin versus 19, 62, 50 and 24 nM for sitagliptin,
vildagliptin, saxagliptin and alogliptin, respectively) [9]. In
healthy male volunteers, linagliptin (2.5-600 mg) demon-
strated dose-dependent inhibition of DPP-4 over 24 hours
with a 5 mg dose inhibiting 86.1% of the enzyme activity
[13]. It is important to note that the inhibition ≥ 80% of
DPP-4 activity is the level which leads to the maximum
glucose reduction [14].
In plasma, most gliptins exhibit low binding rate to
proteins [9]. Linagliptin, in turn, extensively binds to
plasma proteins, and at the therapeutic dose of 5 mg,
most of the drug is bound to proteins [9]. Among the
drugs in this class, linagliptin, sitagliptin and alogliptin
do not show appreciable metabolism in vivo; about 80%
of the dose is eliminated unchanged [9]. In plasma, only
the pharmacologically inactive metabolite CD18790 rep-
resents over 10% of the total drug concentration [15].
Unlike other DPP-4 inhibitors, linagliptin excretion is
not performed by the kidneys, but rather through the
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excretion may be in part because of the high plasma
protein binding [9]. The implication of this mode of
linagliptin excretion is that in patients with kidney dis-
ease, no dose adjustment is required [8].
Clinical studies: efficacy assessment
Monotherapy
Although metformin is the first-line drug in the early
pharmacological treatment of T2DM, some patients do
not tolerate the drug, or exhibit contraindications [16].
In these cases, the DPP-4 inhibitors such as linagliptin
can be an effective option for use as monotherapy.
The efficacy of linagliptin as monotherapy, compared
to placebo, was assessed in two studies of 12 and 24
weeks [17,18]. The linagliptin was significantly more ef-
fective than placebo in reducing glycated hemoglobin
(HbA1c). Also independent of baseline HbA1c, the re-
sults were favorable for linagliptin; for baseline HbA1c
≥ 9.0%, 8.0% to < 9.0%, 7.5% to < 8.0% and <7.5%, the
respective placebo-adjusted mean changes were −1.1%
(p < 0.0001), -0.71% (p < 0.0001), -0.55% (p < 0.005)
and −0.57 (p < 0.0001) [18].
The results of linagliptin monotherapy were also better
than placebo in the secondary endpoints. There was
more reduction in fasting plasma glucose (FPG) and 2-
hour postprandial glucose (2hPPG) in the linagliptin
group. The adjusted mean change in FPG was −1.3
mmol/L (p < 0.0001), and in 2hPPG was −3.2 mmol/L
(p < 0.0001). The percentage of patients with HbA1c < 7%
after 24 weeks was 25.2% (77/306) in the linagliptin group
compared to 11.6% (17/147) in the placebo group (OR =
2.9, p = 0.0006) [18]. Besides, there was significant im-
provement in β-cell function markers (HOMA-%β, C-
peptide, proinsulin-to-insulin ratio, and disposition index
[DI]) in those receiving linagliptin [17,18].
Kawamori et al. also compared linagliptin monotherapy
with voglibose, an α-glucosidase inhibitor, in a 26-week
study [17]. More patients receiving linagliptin achieved
HbA1c ≤ 7% (30.3%) when compared to voglibose (22.2%)
[10]. The percentage of patients achieving a reduction ≥
0.5% in HbA1c with linagliptin (57.2%) was also greater
than those with voglibose (37.7%) (p < 0.0001) [10].
Combination therapy
 Combination with metforminFigure 2 Change over time in HbA1c, following treatment with
linagliptin 5 mg or placebo for 24 weeks (reproduced from
Taskinem et al.) [21].Metformin is considered first-line therapy in most
guidelines around the world. Following 3 years of
T2DM diagnosis, approximately 50% of patients
will require combination therapy [19]. Thus, the
combination of metformin with another agent
which complements its action will be performed in
most type 2 diabetes patients. Graefe-Mody et al.evaluated in a randomized, open-label, crossover,
single-center study, the potential pharmacokinetic
and pharmacodynamic interaction between
metformin and linagliptin. The coadministration of
metformin 850 mg, three times daily and
linagliptin (10 mg once daily) did not modify the
pharmacological profile of each drug alone. This
study suggested that the combination of
metformin and linagliptin can be done safely in
patients with T2DM, without requiring dose
adjustment [20].
In a 24-week study with about 700 patients, the
addition of linagliptin to the therapeutic regimen in
diabetic patients inadequately controlled on
metformin, HbA1c reduction from baseline was
0.64% with the linagliptin versus placebo. The
Figure 2 exhibits the HbA1c change over time [21].
The adjusted mean reduction in FPG was 1.2 mmol/
L in the group with added linagliptin, and in 2hPPG
was 3.7 mmol/L (p < 0.0001 for all comparisons)
[22]. In another 12-week assessment, linagliptin
5 mg (single daily dose) was added to the metformin
treatment (n = 333 patients), and was significantly
more effective than placebo and the 1-mg or 10-mg
doses [23].
Haak et al. reported the findings of early
combination of linagliptin and metformin in
treatment-naïve diabetic patients, in a 24-week
double-blind study [22]. Compared to metformin
monotherapy (1000 mg), the early combination of
metformin (1000 mg) and linagliptin (5 mg) was
more effective in reducing HbA1c (−1.7%
versus −0.8%, p <0.0001). Substantial reduction in
FPG from baseline to Week 24 was found with the
combination therapy [22].
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Linagliptin was also evaluated in combination with
pioglitazone, in a 24-week investigation (n = 389
patients). The addition of linagliptin (5 mg) to
pioglitazone (30 mg), both administered in a single
daily dose, caused an adjusted mean placebo-
corrected reduction of 0.5% in HbA1c levels from
baseline at the end of 12 weeks, remaining constant
until the 24th week. The group receiving the
linagliptin/pioglitazone combination showed more
significant reductions in FPG than placebo/
pioglitazone group (p < 0.0001) [24]. More patients
in the linagliptin/pioglitazone group (42.9%)
achieved the target HbA1c < 7%, compared to the
placebo-pioglitazone group (30.5%, p < 0.0051). The
HbA1c reduction was greater in patients with
baseline HbA1c ≥ 9% and treated with linagliptin in
combination with pioglitazone (−1.49%). Body
weight remained stable up to 24 weeks in the two
groups. This combination can be interesting, even
for early therapy in patients with an intolerance or
contraindication to metformin.
 Combination with sulfonylurea
In patients inadequately controlled on sulfonylurea
alone, the addition of linagliptin 5 mg (single daily
dose) proved more effective than the combination
with placebo [25]. In this double-blind study, 245
patients were randomized to receive linagliptin
(n = 161) or placebo (n = 84) for 18 weeks. The
HbA1c reductions were significant in favor of
linagliptin at Weeks 6, 12 and 18 (p < 0.0001) [26].
 Triple Combination
The progressive failure of the pancreatic β-cell
function contributes to evolutive character of the
disease and the need for therapeutic adjustment. After
3 years of diagnosis, about 50% of diabetic patients
will require combination therapy [19]. In a
randomized, double-blind, placebo-controlled
study, investigators have screened 1058 T2DM
patients inadequately controlled on metformin
(>1500 mg/day) and sulfonylurea (maximum tolerated
dose) to receive the combination with linagliptin
5 mg (single daily dose) or placebo [27]. Assessing the
total patients included, the adjusted mean change in
HbA1c level was −0.72% in the linagliptin group
compared with −0.10% in the placebo group, resulting
in a difference of −0.62% (p < 0.0001) with placebo.
Fewer patients receiving linagliptin required rescue
therapy compared with placebo (5.4 versus 13.0%).
More patients on linagliptin also achieved the target
HbA1c. The importance of this study in practice is
the possibility to improve glycemic control in patients
already receiving two oral antidiabetic agents and who
are outside the proposed targets [27].Comparison with sulfonylurea
The DPP-4 inhibitors promote glucose-dependent insulin
secretion, i.e., in the presence of lower blood glucose
values, the insulin release is not expected, which contrib-
utes to reduce the risk of hypoglycemia [16]. The sulfonyl-
ureas, in turn, are more associated with hypoglycemia
since they do not exhibit glucose-dependent mechanism
of action. In a 12-week analysis, 333 T2DM patients in-
adequately controlled on metformin monotherapy were
randomized to receive linagliptin or glimepiride, in a
single daily dose [25]. After 12 weeks, HbA1c has de-
creased both in the linagliptin or glimepiride groups.
This study showed that linagliptin has the same efficacy





DPP-4 inhibitors have a low risk of hypoglycemia
due to their effect as glucose-dependent insulin
secretagogue. The incidence of hypoglycaemia was
8.2% in patients receiving linagliptin and 5.1% in
those receiving placebo. The somewhat higher
incidence of hypoglycaemia associated with
linagliptin was almost exclusively attributable to the
combination with sulphonylurea. In studies where
patients were receiving sulphonylurea, the incidence
of hypoglycaemia was 20.7% and 13.3% in the
linagliptin- and placebo-treated groups, respectively;
notably, 38% of patients on sulphonylurea
background therapy accounted for 96% of all
hypoglycaemic events in the linagliptin-treated
group [28]. As observed with other gliptins, the
combination with linagliptin to patients inadequately
controlled on metformin + sulfonylurea showed a
higher occurrence of hypoglycemia than the placebo
group (22.7% versus 14.8%) [27].
 Weight gain
The T2DM treatment with glitazone, sulfonylurea,
or insulin may be associated with weight gain.
Most T2DM patients are overweight or obese, so
it is not desirable to gain additional weight due to
the treatment. DPP-4 inhibitors have a neutral
effect on body weight [8]. Linagliptin showed no
weight increase in monotherapy or in combination
with metformin. In combination with pioglitazone,
the linagliptin was associated with greater weight
gain than placebo (2.3 kg versus 1.2 kg, p < 0.01),
in a 24-week study, but these changes were
minimal from baseline [24]. There was also no
change in waist circumference with linagliptin
treatment [24].
Table 2 Potential cardiovascular benefits of DPP-4
inhibitors [38]
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The adverse events most frequently reported with
DPP-4 inhibitors are mild infections (such as
nasopharyngitis, urinary tract infection, and upper
respiratory tract infections) and diarrhoea, back
pain, headache and hypertension. Data presented
with linagliptin indicate an overall incidence similar
to placebo for these most frequently observed
adverse events [28].
In 2008, the FDA (Food and Drug Administration)
recommended the inclusion of a warning on the package
insert of some drugs acting on the incretin system, after
case reports of pancreatitis with the use of GLP-1 ana-
logs [29]. Postmarketing analyses have also identified
isolated cases of pancreatitis with DPP-4 inhibitors, but
a cause-effect relationship was not identified. It is
important to consider that patients with T2DM and
hypertriglyceridemia exhibit increased risk of pancrea-
titis [7]. In clinical studies, 8 pancreatitis cases were
reported in 4687 patients on linagliptin and no cases
among 1183 patients receiving placebo; however, no re-
lationship between linagliptin and pancreatitis has been
established [13].
Despite the therapeutic dose used in practice being 5 mg,
in a single daily dose, there seems to be no increased
incidence of adverse events with increasing doses of
linagliptin. Also, no changes in laboratory parameters or
vital signs were observed in different studies with the drug.
Moreover, the incidence of cutaneous and subcutaneous
changes in linagliptin clinical trials was low when compared
to placebo (0–1.3% versus 0–0.9%) [13].
Patients with renal impairment
Linagliptin administration to patients with renal impair-
ment does not require dosage adjustment [6]. When ad-
ministered in a 5 mg dose, less than 1% of linagliptin
is excreted unchanged in the urine. Thus, in therapeutic
dose, renal excretion is a minor route of elimination for
linagliptin, unlike other DPP-4 inhibitors [30]. When tested
in patients with mild (creatinine clearance > 50 to ≥
80 mL/min), moderate (creatinine clearance > 30 to ≤ 50
mL/min), and severe (creatinine clearance < 30 mL/min)
renal impairment, in addition to the end-stage renal disease
(creatinine clearance < 30 mL/min on hemodialysis), renal
excretion of linagliptin remained unchanged and represents
less than 7% in all groups [31]. In an analysis of 3 Phase III,
randomized, placebo-controlled studies, the effect of renal
function on the efficacy and safety of linagliptin was evalu-
ated. Patients (n = 2141) were grouped according to renal
function, and it was found that reductions in HbA1c with
linagliptin did not differ among groups (mild, moderate, or
severe renal impairment), as well as adverse event occur-
rences that were similar to placebo [31,32].Patients with liver failure
Linagliptin administration to patients with liver failure
does not require dose adjustment. Although reductions
occur in the linagliptin pharmacokinetic parameters as
the liver failure degree increases, this has no impact on
DPP-4 inhibition [6].
Elderly patients
No changes were observed in safety and tolerability of
linagliptin in patients aged over 65 years [6].
Cardiovascular safety
The main cause of mortality in T2DM patients is
cardiovascular disease (CVD) [33]. The gliptins may
exert beneficial cardiovascular effects through different
mechanisms (Table 2) [34]. Recent studies also demon-
strated that intensive control may be associated with
increased cardiovascular (CV) risk; therefore, another
potential benefit of gliptins would be a low risk of
hypoglycemia [35]. In studies using animal models, acti-
vation of GLP-1 receptor is associated with limiting the
size of the area of myocardial infarction (MI) [36]. Fur-
thermore, linagliptin has anti-oxidant properties, prob-
ably due to its xanthine-based molecular structure [37].
Even when administered in supratherapeutic doses,
linagliptin does not prolong the QT interval [38].
A recent meta-analysis has assessed the cardiovascular
safety profile of linagliptin in patients who participated in
8 Phase III studies. Of the 5239 patients, 3319 received
linagliptin, and 1920 received a comparator (placebo,
glimepiride, voglibose) [35]. A composite of CV death,
stroke, MI, or hospitalization for unstable angina was con-
sidered as the primary endpoint. In the linagliptin group,
the primary endpoint occurred in 11 (0.3%) patients,
whereas in the comparator group there were 23 cases
(1.2%), demonstrating lower risk in those who received
linagliptin. An important conclusion is that, as other DPP-
4 inhibitors have also demonstrated, linagliptin shows no
increase in CV risk [35]. At present, various studies with
DPP-4 inhibitors are currently ongoing to evaluate the
safety and effects on cardiovascular endpoints (Table 3) [8].
Drug interaction
In general, DPP-4 inhibitors have not demonstrated a sig-
nificant activation or inhibition of CYP system enzymes,
Table 3 DPP-4 inhibitors and cardiovascular risk: ongoing
studies (adapted from [8])
Sitagliptin TECOS: Trial Evaluating Cardiovascular Outcomes with
Sitagliptin
Saxagliptin SAVOR: Saxagliptin Assessment of Vascular Outcomes
Recorded in Patients with Diabetes Mellitus Trial
Alogliptin EXAMINE: Examination of Cardiovascular Outcomes:
Alogliptin vs Standard of Care in Patients with Type 2
Diabetes Mellitus and Acute Coronary Syndrome
Linagliptin CAROLINA: Cardiovascular Outcome Study of
Linagliptin Versus Glimepiride in Patients with Type 2
Diabetes
Guedes et al. Diabetology & Metabolic Syndrome 2013, 5:25 Page 6 of 7
http://www.dmsjournal.com/content/5/1/25suggesting low potential for interaction with drugs metabo-
lized by this pathway (except saxagliptin) [9]. Linagliptin is
a substrate for CYP3A4/5, and CYP3A4 inhibition or
induction by concomitant administration of other drugs
would not cause significant change in exposure to linag-
liptin. Additionally, as linagliptin is just a weak competitive
inhibitor of CYP3A4, there would be a less than 2-fold de-
crease in the clearance of other drugs metabolized by this
pathway, so linagliptin is considered as having low poten-
tial for clinically relevant interactions [15].
In different pharmacokinetic drug-drug interaction
studies, linagliptin exhibited low potential for drug inter-
action [10]. Linagliptin did not change the pharmacoki-
netic steady state of ethinyl estradiol, levonorgestrel,
digoxin, warfarin, glyburide, pioglitazone, simvastatin,
and metformin [10]. Rifampicin, in turn, can reduce the
exposure to linagliptin, suggesting that linagliptin effi-
cacy may be reduced by concomitant use of these two
drugs [12].Conclusions
Currently, DPP-4 inhibitors represent an important tool
in the T2DM therapeutic setting, both for their efficacy
in glycemic control, as well as for their safety profile. Re-
garding the effect on glycemic control, no significant
differences have been evidenced among the gliptins.
Linagliptin is a potent, long-acting, orally active DPP-4
inhibitor, with demonstrated efficacy as monotherapy
and in combination therapy with other oral antidiabetic
agents, when administered in a single daily dose. The
primarily non-renal route of elimination of linagliptin
differenciate it from other drugs in the same class; pa-
tients with kidney disease of any degree do not require
dose reduction of linagliptin. The risk of adverse events
with linagliptin monotherapy is similar to placebo. Its
effect on body weight is considered neutral and the hypo-
glycemia occurrence is very low. Therefore, linagliptin can
contribute to the achievement of glycemic targets, with
safety and tolerability, even in special difficult-to-manage
situations, as in those patients with renal impairment.Abbreviations
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